News | December 25, 2025
Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Subscribe To Our Newsletter & Stay Updated
